================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

     [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
          ACT OF 1934

                For the quarterly period ended February 28, 2009

     [ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from _____ to _______

                       Commission File Number: 333-107179

                              Mammatech Corporation
                              ---------------------
             (Exact Name of Registrant as Specified in its Charter)

                   Florida                               59-2181303
                   -------                               ----------
       (State or other jurisdiction of                (I.R.S. Employer
        incorporation or organization)               Identification No.)

                    930 NW 8th Ave Gainesville, Florida 32601
                    -----------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

        Registrant's telephone number including area code: (352) 375-0607

                                       N/A
                  ---------------------------------------------
              Former name, former address, and former fiscal year,
                          if changed since last report

Indicate by check mark whether the registrant (1) filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definition of "large accelerated filer", "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Larger accelerated filer  [ ]                     Accelerated filer  [ ]
Non-accelerated filer  [ ]                        Smaller reporting company  [X]

Indicate by check mark whether registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: 5,427,625 shares of common
stock, par value $0.0001, outstanding as of April 20, 2009.

================================================================================

<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>

                                       MAMMATECH CORPORATION

                                               Index

                                                                                                 Page
                                                                                                 ----

Part I - FINANCIAL INFORMATION

Item 1.    Financial Statements

           Balance Sheets at February 28, 2009 (unaudited) and August 31, 2008                     1

           Statements of Operations for the three months and six months ended February 29, 2008    2
           and February 28, 2009 (unaudited)

           Statements of Cash Flows for the six months ended February 29, 2008 and February 28,    3
           2009 (unaudited)

           Notes to Financial Statements (unaudited)                                               4

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operation    5

Item 3.    Quantitative and Qualitative Disclosures About Market Risk                              8

Item 4.    Controls and Procedures                                                                 8


Part II - OTHER INFORMATION

Item 1.    Legal Proceedings                                                                       9

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds                             9

Item 3.    Defaults upon Senior Securities                                                         9

Item 4.    Submission of Matters to a Vote of Security Holders                                     9

Item 5.    Other Information                                                                       9

Item 6.    Exhibits                                                                                9

SIGNATURES                                                                                         10


                                               i

<PAGE>



                                            PART I - FINANCIAL INFORMATION


                                                 Mammatech Corporation
                                                    Balance Sheets


                                                                       February 28,          August 31,
                                                                           2009                 2008
                                                                       ------------         -----------
                                                                       (Unaudited)
ASSETS
Current assets:
  Cash                                                                  $   275,616         $   335,427
  Accounts receivable trade                                                  38,408              88,191
  Inventory                                                                  63,769              63,332
                                                                        -----------         -----------
      Total current assets                                                  377,793             486,950
                                                                        -----------         -----------

Property and equipment, at cost, net of
   accumulated depreciation of $313,824
   and $303,824                                                             243,832             253,432
                                                                        -----------         -----------

Available for sale securities                                               106,300             193,198

Other assets                                                                  4,652               4,652
                                                                        -----------         -----------
                                                                            110,952             197,850
                                                                        -----------         -----------
TOTAL ASSETS                                                            $   732,577         $   938,232
                                                                        ===========         ===========

LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities:
  Accounts payable and accrued expenses                                 $    53,301         $    38,706
  Accounts payable and accrued salaries - officers                        1,201,409           1,148,599
                                                                        -----------         -----------
      Total current liabilities                                           1,254,710           1,187,305
                                                                        -----------         -----------

Stockholders' (deficit):
 Common stock, $.0001 par value,
  200,000,000 shares authorized, 5,427,625 issued
  and 5,123,700 outstanding                                                     543                 543
 Additional paid-in capital                                               2,896,186           2,896,186
 Accumulated (deficit)                                                   (3,148,816)         (2,962,653)
                                                                        -----------         -----------
                                                                           (252,087)            (65,924)
 Treasury stock, at cost, 303,925 shares                                   (148,051)           (148,051)
                                                                        -----------         -----------
                                                                           (400,138)           (213,975)
Other comprehensive income:
 Unrealized gain (loss) on marketable securities                           (121,995)            (35,098)
                                                                        -----------         -----------
                                                                           (522,133)           (249,073)
                                                                        -----------         -----------
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)                           $   732,577         $   938,232
                                                                        ===========         ===========


                   The accompanying notes are an integral part of these financial statements.

                                                   1



<PAGE>


                                                           Mammatech Corporation
                                                   Statements of Comprehensive Operations
                                   Three and Six Months Ended February 29, 2008 and February 28, 2009
                                                               (unaudited)

                                                               Three months                            Six Months
                                                                   2008               2009                2008              2009
                                                              -----------        -----------        -----------        -----------

Sales, net                                                     $    93,787        $    50,766        $   178,267        $   141,735
Cost of sales                                                       34,573             50,728             57,664             99,527
                                                               -----------        -----------        -----------        -----------
Gross profit                                                        59,214                 38            120,603             42,208
                                                               -----------        -----------        -----------        -----------

Selling, general and administrative expenses                        71,055            124,109            194,463            240,254
                                                               -----------        -----------        -----------        -----------
(Loss) from operations                                             (11,841)          (124,071)           (73,860)          (198,046)


Other income and (expense):
  Gain (loss) on sale of investment securities                        --                 --                 (279)               --
  Interest and dividend income                                       8,013              8,664             16,080             11,883
                                                               -----------        -----------        -----------        -----------
                                                                     8,013              8,664             15,801             11,813
                                                               -----------        -----------        -----------        -----------

(Loss) before income taxes                                          (3,828)          (115,407)           (58,059)          (186,163)
Provision for income taxes                                            --                 --                 --                 --
                                                               -----------        -----------        -----------        -----------
Net (loss)                                                     $    (3,828)       $  (115,407)       $   (58,059)       $  (186,163)
                                                               ===========        ===========        ===========        ===========

Basic and fully diluted earnings per share:
 Net  (loss)                                                   $      (0.0)       $     (0.02)       $     (0.01)       $     (0.03)
                                                               ===========        ===========        ===========        ===========
 Weighted average shares                                         5,427,625          5,427,625          5,427,625          5,427,625
                                                               ===========        ===========        ===========        ===========

  Net income (loss)                                            $    (3,828)       $  (115,407)       $   (58,059)       $  (186,163)
 Unrealized (loss) from investments, net income
    taxes                                                          (10,580)           (11,640)           (15,581)           (86,897)
                                                               -----------        -----------        -----------        -----------
  Comprehensive (loss)                                         $   (14,408)       $  (127,047)       $   (73,640)       $  (273,060)
                                                               ===========        ===========        ===========        ===========


                            The accompanying notes are an integral part of there financial statements.

                                                                 2

<PAGE>


                                                  Mammatech Corporation
                                                 Statements of Cash Flows
                                  Six Months Ended February 29, 2008 and February 28, 2009

                                                      (Unaudited)

                                                                             2008                  2009
                                                                          ---------             ---------

Net (loss)                                                                $ (58,059)            $(186,163)
  Adjustments to reconcile net (loss) to net cash
   provided by (used in) operating activities:
   Depreciation and amortization                                             10,000                10,000
   Realized loss on marketable securities                                       279                  --
Changes in assets and liabilities:
   Decrease in accounts receivable, trade                                     6,946                49,783
    (Increase) decrease in inventory                                          2,302                  (437)
    Decrease in other assets                                                   (581)                 --
    Increase in accounts payable and accrued salaries - officers             52,810                52,810
    Increase (decrease) in accounts payable and accrued expenses            (10,067)               14,595
                                                                          ---------             ---------
  Net cash provided by (used in) operating activities                         3,630               (59,412)
                                                                          ---------             ---------

Cash flows from investing activities:
   Purchase of available for sale securities                                (15,820)             (152,022)
   Proceeds from the sale of available for sale securities                   10,190               152,023
   Purchase of fixed assets                                                  (2,085)                 (400)
                                                                          ---------             ----------
Net cash provided by (used in) investing activities                          (7,715)                 (399)
                                                                          ---------             ---------

Cash flows from financing activities:
Net cash (used in) financing activities                                        --                    --
                                                                          ---------             ---------

(Decrease) in cash                                                           (4,085)              (59,811)

Cash and cash equivalents,
 beginning of period                                                        327,889               335,427
                                                                          ---------             ---------
Cash and cash equivalents,
 end of period                                                            $ 323,804             $ 275,616
                                                                          =========             =========


                The accompanying notes are an integral part of these financial statements

                                               3
<PAGE>


                             MAMMATECH CORPORATION
                          NOTES TO FINANCIAL STATEMENTS
                                FEBRUARY 28, 2009
                                   (UNAUDITED)

(1)      Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles (GAAP) for interim financial
information and Article 8 of Regulation S-X. They do not include all of the
information and footnotes required by GAAP for complete financial statements. In
the opinion of management, all adjustments (consisting only of normal recurring
adjustments) considered necessary for a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year. For further
information, refer to the financial statements of the Company as of August 31,
2008, and for the two years then ended, including notes thereto included in the
Company's Form 10-KSB.

(2)      Use of Estimates

The preparation of the Company's financial statements requires management to use
estimates and assumptions. These estimates and assumptions affect the reported
amounts in the financial statements and accompanying notes. Actual results could
differ from these estimates.

(3)      Reclassifications

Certain reclassifications have been made to the prior year financial statements
in order to conform to current year presentation. Training professional fees
have been reclassified in the current fiscal year from selling ,general, and
administrative cost to cost of sales. Training professional in February 2008
and 2009 are 17,391 and 8,655 respectively.

(4)      Earnings Per Share

The Company calculates net income (loss) per share as required by Statement of
Financial Accounting Standards (SFAS) 128, "Earnings per Share." Basic earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares outstanding for the period. Diluted earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares and dilutive common stock equivalents
outstanding. During periods when anti-dilutive commons stock equivalents are not
considered in the computation.

(5)      Inventory

Inventory is stated at the lower of cost, determined on a first in, first out
basis, or market value. Inventory consists principally of finished goods and
packaging materials.

(6)      Available For Sale Securities

Marketable securities consist of the following at February 28, 2009: Mutual
funds and equity securities with a fair market value of $106,300. The cost basis
of these securities is $228,295. The unrealized holding losses on
available-for-sale securities included in accumulated other comprehensive income
as a component of stockholders' equity decreased by $86,898 during the six
months ended February 28, 2009, and $15,581 at February 29, 2008.


                                       4
<PAGE>


ITEM 2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
              CONDITION AND RESULTS OF OPERATIONS


Forward-Looking Statements

The following discussion should be read in conjunction with the accompanying
financial statements and notes thereto included within this Quarterly Report on
Form 10-QSB. In addition to historical information, the information in this
discussion contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. These forward-looking statements involve risks
and uncertainties, including statements regarding the Company's capital needs,
business strategy and expectations. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such
as "may", "will", "should", "expect", "plan", "Intend", "anticipate", "believe",
estimate", "predict", "potential" or "continue", the negative of such terms or
other comparable terminology. Actual events or results may differ materially. In
evaluating these statements, you should consider various factors described in
this Quarterly Report, including the risk factors accompanying this Quarterly
Report, and, from time to time, in other reports the Company files with the
Securities and Exchange Commission. These factors may cause the Company's actual
results to differ materially from any forward-looking statement. The Company
disclaims any obligation to publicly update these statements, or disclose any
difference between its actual results and those reflected in these statements.
The information constitutes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.

Company Background

The Company is engaged in the sale of a patented breast tumor detection training
system (the "MammaCare System"). Using life-like models of a human female
breast, the MammaCare System is designed to train individuals to perform
effective manual breast examination. The breast models contain simulated tumors
of varying sizes, ranging from under 5mm to over 10mm. They also contain
material which simulates the normal nodularity, or "lumpiness," that
characterizes most breast tissue.

Although the examiner can never determine by feel alone whether a lump is benign
or malignant, detection of tumors in the size range simulated by the models is
important to early diagnosis of malignancies. Thus, the Company believes that by
training women to palpate the breast model (and their own breasts) properly, the
MammaCare System will lead to early detection of breast cancer and thus reduce
morbidity and mortality due to this disease.

The MammaCare System is sold in several forms, all of which contain at least one
of the Company's patented breast models. Originally, a client was given private
training after which she was provided with a take-home breast model and other
materials. Now, the customer may view a video tape developed by the Company
which teaches her the proper use of the model(s) and an extremely thorough
examination technique. The practice model is designed to permit a woman to
reinforce her lump detection skills periodically and serves as a comparative
standard as she palpates her own breast.

The Company's primary marketing strategy is designed to encourage sales through
physicians, hospitals and diagnostic centers. Under this marketing approach,
health care providers purchase the MammaCare Professional Learning System
directly from the Company. The Company does not generate any revenues from the
use of the Learning System by women, and the Company's sole revenues come from
sales of MammaCare System and any accompanying training.

The MammaCare Professional Learning System consists of a teaching model, a
24-minute video cassette, and practice kit. The teaching model is a patented
breast model, designed to teach the difference between the feel of normal,
nodular breast tissue and the feel of small lesions. The video cassette guides
the learner through a series of step-by-step exercises, first on the models,
then on her own breast tissue. This is intended to lead to mastery level


                                       5

<PAGE>


proficiency in palpation, search technique and lump detection. The practice kit
contains a "take-home" breast model, a written review manual, a reminder
calendar and a record booklet.

A patient may purchase the practice kit portion of the MammaCare System for
continued monthly reinforcement of her skills. Patients may view the videotape
either in their homes or in the provider's facility. In either case, a patient
should have her proficiency reviewed by a physician or certified MammaCare
Specialist.

By obtaining the MammaCare System from their own providers, patients are assured
of receiving the full quality of MammaCare without the inconvenience and expense
of a lengthy clinic visit. Further, it is anticipated that the cost of MammaCare
to the public will be lower than historical prices charged for clinical
services. However, while the Company has made providers aware of the need to
keep the price of MammaCare reasonable, the providers are free to charge
whatever fee they deem appropriate for the use of the MammaCare System. In light
of the fact that most health insurance policies do not reimburse patients for
any portion of their MammaCare expenses, no assurance can be given that the
physicians will set prices low enough to attract patients.

To date, there are over 1,000 physicians, hospitals and diagnostic centers
throughout the United States providing the Learning System to women. No
assurances can be given that the Company's marketing approach will be
successful. For the Company to achieve profitability, MammaCare must be provided
to an ever increasing number of women.

Recent Developments

During the year ended August 31, 2008 fiscal year, the Company trained and
certified 17 MammaCare Specialists, 29 MammaCare Clinical Breast Examiners and
109 MammaCare Breast Self Exam (BSE) Instructors. During the three months ended
February 28, 2009, the Company trained and certified 5 MammaCare Specialists, 1
MammaCare Clinical Breast Examiners and 22 MammaCare Breast Self Exam (BSE)
Instructors. Fourteen of the 22 new BSE certifications were related to the
Company's German affiliate. During the first six months of the current year, the
Company certified 15 MammaCare Specialists, one MammaCare Clinical Breast
Examiner, and 36 MammaCare BSE instructors.

The Company is continuing to pursue its strategy of establishing additional
training sites both in the United States and abroad.

The Company continues to expend resources to complete development of its
patented tactile computer technology tentatively termed the Palpation Assessment
Device (PAD). The PAD is the first computer-based system that teaches and
evaluates manual breast examination skills. Currently, the PAD continues to
undergo testing as part of the MammaCare training programs. MammaCare PAD
technology has been sited in a number of academic institutions. Its first
operational deployment is at the Florida State University Medical School in
Tallahassee where it is being used to train first- and second-year medical
students. However, there can be no assurances that significant income will
result from these programs or that additional training institutions will acquire
the service.

After the close of the second quarter, the Company made its MammaCare Personal
Learning System available to the public on Amazon. com. Again, forecasts of
revenue resulting from this marketing effort are both premature and uncertain.

The Company continues to seek a larger partner in the healthcare industry to
increase the distribution of its products.


                                       6

<PAGE>


Results of Operations

Comparison of Three Months Ended February 28, 2009 and February 29, 2008
------------------------------------------------------------------------

The Company's net sales were $50,766 for the three months ended February 28,
2009 compared to$93,787 during the three months ended February 29, 2008, a
decrease of approximately 46% from the prior period. Gross profit for the three
months ended February 28, 2009 and 2008 was $38 and $86,442, respectively, a
decrease of approximately 100% from the prior period, due largely to increased
costs of trainings. Gross profit margin for the three months ended February 28,
2009 and 2008 was 0.0% and 92%, respectively.

Selling, general and administrative expenses increased from $98,283 for the
three months ended February 29, 2008 to $124,109 for the three months ended
February 28, 2009. Selling, general and administrative expenses remained
essentially the same , during the same period last year the Company had
approximately $ 30,000 reimbursed from a National Institutes of Health grant,
that ended March 31, 2009. Loss from operations for the three months ended
February 28, 2009 and 2008 was ($124,071) and ($11,841), respectively, an
increase of approximately 948% from the prior period. The Company had a net loss
of ($117,077) for the three months ended February 28, 2009 and net loss of
($3,828) for the three months ended February 29, 2008, an increase of
approximately 3958 %.


Comparison of Six months Ended February 28, 2009 and February 29, 2008
----------------------------------------------------------------------

The Company's net sales were $141,735 for the six months ended February 28, 2009
compared to $178,267 during the six months ended February 29, 2008, a decrease
of approximately 20% from the prior period. During the period ending February
28, 2009 the Company experienced lower sales due to a decrease in the overall
economy, less monies available to state health departments. State Health
Departments account for a large percentage of sales to the Company. Gross profit
for the six months ended February 28, 2009 and 2008 was $42,208 and $147,831
respectively, a decrease of approximately 71% from the prior period due to a
combination of lower sales and a reclassification of professional fees from
selling, general and administrative expenses to cost of sales. Gross profit
margin for the six months ended February 28, 2009 and February 28, 2008 was 30%
and 83%, respectively.

Selling, general and administrative expenses increased from $221,691 for the six
months ended February 29, 2008 to $240,254 for the six months ended February 28,
2009. Loss from operations for the six months ended February 28, 2009 and
February 29, 2008 was $198,046 and $73,860 respectively. which resulted to an
increase of $168% from the prior year.

The Company has a net loss of ($58,059) for the six months ended February 29,
2008 and net loss of ($187,833) for the six months ended February 28, 2009. This
change was primarily due in a decrease in gross sales for the quarter ending
February 28, 2009.


                                       7
<PAGE>


Liquidity and Capital Resources

The Company has no immediate liquidity problems. At February 28, 2009, the
Company had cash on hand of $275,616 and marketable securities of $106,300. At
February 28, 2009, the Company has accounts payable and accrued salaries owing
to its officers of $1,201,409. During the three months ended February 28, 2009,
the Company had net loss of $117,077 and an unrealized loss from investments of
$11,640.

The Company intends to use its capital resources to fund its product development
and to expand distribution. The Company believes these capital resources are
sufficient to allow the Company to attract potential interest from a strategic
partner and to make it an attractive candidate for grant funding from public and
private sources. However, there can be no assurance these capital resources will
be sufficient to allow the Company to implement its marketing strategies or to
become profitable.


Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.


ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

         N/A

ITEM 4.  Controls and Procedures

         (a) During the fiscal period covered by this report, our management,
with the participation of the Chief Executive Officer and Chief Financial
Officer of the Company, carried out an evaluation of the effectiveness of the
design and operation of our disclosure controls and procedures (as defined in
Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act")). Based on such evaluation, our Chief Executive Officer and
Chief Financial Officer have concluded that, as of the end of the period covered
by this report, our disclosure controls and procedures are effective to ensure
that information required to be disclosed by us in reports that we file or
submit under the Exchange Act is recorded, processed, summarized and reported
within the required time periods and are designed to ensure that information
required to be disclosed in our reports is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate to allow timely decisions regarding required disclosure.

         (b) There was no change in our internal control over financial
reporting (as defined in Rule 13(a)-15(e)) that occurred during the quarter
ended February 28, 2009 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.


                                       8
<PAGE>


                           PART II - OTHER INFORMATION


Item 1.  LEGAL PROCEEDINGS

         No legal proceedings are pending or threatened to the best of our
knowledge.

Item 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

         None

Item 3.  DEFAULTS UPON SENIOR SECURITIES

         None

Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None

Item 5.  OTHER INFORMATION

         None

Item 6.  EXHIBITS

         The following is a complete list of exhibits filed as part of this Form
10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601
of Regulation S-K.

         31       Certification of Chief Executive Officer pursuant to
                  Section 302 of the Sarbanes-Oxley Act of 2002.

         32       Certification of Chief Executive Officer pursuant to
                  Section 906 of the Sarbanes-Oxley Act of 2002.


                                       9
<PAGE>


SIGNATURES

         In accordance with the requirements of Section 12 of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                         MAMMATECH CORPORATION


                                         By: /s/   Henry Pennypacker
Dated: April 20, 2009                        -----------------------------------
                                              Henry Pennypacker,
                                              Chief Executive Officer

                                         By: /s/   Mary B. Sellers
Dated: April 20, 2009                        -----------------------------------
                                             Mary B. Sellers
                                             Chief Financial Officer


                                       10
</TABLE>